Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Promedior
Lexington, Massachusetts, United Statespromedior.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Promedior is a clinical-stage biotechnology company pioneering the development of targeted therapeutics for the treatment of fibrosis. The company's lead product candidate, PRM-151 (zinpentraxin alfa), is a recombinant form of the endogenous human protein pentraxin-2 that prevents and reverses fibrosis by modulating monocyte differentiation. Promedior's pipeline targets a broad range of systemic fibrotic diseases, including idiopathic pulmonary fibrosis and myelofibrosis. In 2020, the company was acquired by Roche for an upfront payment of $390 million plus potential milestone payments totaling up to $1 billion.
- Therapeutic areas
- HematologyPulmonology
- Modalities
- Recombinant proteinBiologic
- Industry
- Biotech
02
Partnerships
Beyond the preview
Go deeper on Promedior.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Promedior.